DAWN
Day One Biopharmaceuticals, Inc.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Apr 23. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q2 2026: 0 added (0 new), 29 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.190 → −$0.172 over 90 days. 1 up, 3 down in 30 days.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | $0.00 |
| JPMORGAN CHASE & CO | EXIT | $0.00 |
| DIMENSIONAL FUND ADVISORS LP | EXIT | $0.00 |
| MORGAN STANLEY | EXIT | $0.00 |
| BANK OF AMERICA CORP /DE/ | EXIT | $0.00 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | $0.00 |
| GOLDMAN SACHS GROUP INC | EXIT | $0.00 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | $0.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Mar 2026| Date | Firm | Rating |
|---|---|---|
| Mar 11, 2026 | JP Morgan DOWNGRADE | Neutral |
| Mar 10, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Mar 9, 2026 | Wedbush DOWNGRADE | Neutral |
| Mar 6, 2026 | Jones Trading DOWNGRADE | Hold |
| Mar 6, 2026 | Needham DOWNGRADE | Hold |
| Feb 25, 2026 | Wedbush MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Grossman William Director Apr 23, 2026 | TO ISSUER | 32,335 sh |
Merendino Lauren Chief Commercial Officer Apr 23, 2026 | TO ISSUER | 18,978 sh |
Merendino Lauren Chief Commercial Officer Apr 23, 2026 | TO ISSUER | 60,157 sh |
Merendino Lauren Chief Commercial Officer Apr 23, 2026 | TO ISSUER | 330,200 sh |
Nicholson Garry A Director Apr 23, 2026 | TO ISSUER | 33,900 sh |
Nicholson Garry A Director Apr 23, 2026 | TO ISSUER | 15,000 sh |
Grossman William Director Apr 23, 2026 | TO ISSUER | 66,660 sh |
Garland J. Scott Director Apr 23, 2026 | TO ISSUER | 48,072 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.17 | -$0.28–-$0.09 | -6.1% | $54.3M |
| Next Q | -$0.16 | -$0.28–-$0.03 | -11.5% | $57.1M |
| Next FY | -$0.04 | -$0.46–$0.35 | -206.0% | $308.1M |
| Current FY | -$0.76 | -$1.76–-$0.16 | -29.5% | $240.4M |
SecBot reports
5 filings · 1 press release · 1 bullish · 0 bearish · 4 neutral- NEUTRAL 15-12GMay 4, 2026
Day One Biopharmaceuticals filed Form 15 to terminate its SEC registration and suspend reporting…
No further trading or reporting obligations remain; the stock is no longer publicly listed. Monitor for final distributions to former shareholders, if any.
- NEUTRAL 25-NSEApr 23, 2026
Nasdaq has filed Form 25 to delist Day One Biopharmaceuticals (DAWN) common stock, effective…
Shares will cease trading and be removed from Nasdaq; investors should expect final settlement from the acquisition. No further public filings or trading activity will occur.
- NEUTRAL 8-KApr 23, 2026
Day One Biopharmaceuticals (DAWN) was acquired by Servier Pharmaceuticals in an all-cash…
The stock will cease trading and shareholders have received cash proceeds. Monitor Servier's pipeline integration for potential future value in related biotech holdings.
- NEUTRAL 10-K/AApr 17, 2026
This is an amended 10-K filing by Day One Biopharmaceuticals to include Part II and Part III…
The filing is procedurally significant but not financially transformative. Traders should focus on the pending Servier acquisition as the primary catalyst. The option repricing, while a negative…
All DAWN filing & press-release reports (6)
- 15-12G reportMay 4, 2026
- 25-NSE reportApr 23, 2026
- 8-K reportApr 23, 2026
- 10-K/A reportApr 17, 2026
- PRESS-RELEASE reportMar 6, 2026
- 8-K reportFeb 24, 2026